Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Darya-Varia Laboratoria Tbk's Enterprise Value for the quarter that ended in Jun. 2026 was Rp1,237,100 Mil.
PT Darya-Varia Laboratoria Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp182,294 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk EV-to-EBIT Related Terms
PT Darya-Varia Laboratoria Tbk EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:DVLA vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's EV-to-EBIT falls into.
PT Darya-Varia Laboratoria Tbk's current Enterprise Value is Rp1,321,100 Mil.
PT Darya-Varia Laboratoria Tbk's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp182,294 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a EV-to-EBIT of 7.25 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is near median its historical median of 8.00. Over the past decade, PT Darya-Varia Laboratoria Tbk's EV-to-EBIT has ranged from 5.24 to 32.07. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #131 out of 681 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is PT Darya-Varia Laboratoria Tbk's EV-to-EBIT too high?
PT Darya-Varia Laboratoria Tbk's current EV-to-EBIT of 7.25 is near median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.24 to a high of 32.07. The Drug Manufacturers industry median EV-to-EBIT is 16.01. PT Darya-Varia Laboratoria Tbk's value of 7.25 is 54.7% below this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #131 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #131 out of 681 companies for EV-to-EBIT. This places PT Darya-Varia Laboratoria Tbk in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.01. PT Darya-Varia Laboratoria Tbk's value of 7.25 is 54.7% below this benchmark. Historically, PT Darya-Varia Laboratoria Tbk's own EV-to-EBIT has ranged from 5.24 to 32.07 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 16.01, PT Darya-Varia Laboratoria Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current EV-to-EBIT of 7.25 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current EV-to-EBIT is 7.25, which is near median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,868.41, compared to a current price of Rp1,600.00 — trading 14.4% below its estimated fair value. The current EV-to-EBIT is 7.25, which is near median its 10-year median of 8.00 and 54.7% below the Drug Manufacturers industry median of 16.01. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current EV-to-EBIT is 7.25 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,600.00 is trading 14.4% below its estimated GF Value™ of Rp1,868.41.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
EV-to-EBIT: 7.25 (near median its 10-year median of 8.00)
GF Value™: Rp1,868.41 vs. price of Rp1,600.00 (14.4% below fair value)
Industry Position: 54.7% below the Drug Manufacturers median (#131 of 681)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
75GF Score
Get the complete analysis for ISX:DVLA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
